Skip to main content Skip to search Skip to main navigation

Swissmedic: Technical Interpretation on Annex 1 Published

On 31 October 2023, Swissmedic published a Q&A with the title "Interpretation of GMP Annex 1 2022 (Rev. 1)". In the 25-page document, the Swiss Agency for Therapeutic Products provides key answers to questions related to Annex 1, which came into force in August 2023, and to repeatedly asked questions from the previous version.

The interpretation is intended to reflect the "general opinion of the Swiss inspectorates on these topics and serve as support for the inspection of manufacturers of sterile medicinal products." Therefore, the document is of special interest to sterile manufacturers. It is based on the revised Annex 1 of the PIC/S-GMP Guideline (PE 009) which is identical in wording to Annex 1 of the EU GMP Guide except for some minor adjustments.

The technical interpretation answers 46 questions relating to the following chapters of Annex 1:

  • 1. Scope
  • 4. Premises
  • 6. Utilities
  • 7. Personnel/Training
  • 8. Production and Specific Technologies
  • 9. Environmental & Process Monitoring
  • 10. Quality Control (QC)

The document is available in English on the Swissmedic website under the section "Inspectorates".


Source:

Swissmedic: Interpretation of GMP Annex 1 2022 (Rev. 1)

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

In their „Horizon Scanning Report“, EMA and HMA have recommended updates to the regulatory framework to keep pace with developments in radiopharmaceuticals. Due to their unique characteristics these products require specific regulatory and scientific approaches.
Read more
How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:
Read more
Previous
Next